Trial · NCT04587427
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
NCT04587427, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before. Trials, record NCT04587427. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04587427
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
- NCT number
- NCT04587427
- Status
- Completed
- Enrollment
- 1,067 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Bone Metastatic Castration-resistant Prostate Cancer
- Interventions
- Radium 223 dichloride (Xofigo, BAY88-8223)
- First posted
- 2020-10-14
- Last updated
- 2024-03-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients who use radium-223 in combination with abiraterone acetate | Data will be collected from Nov 2013 to Dec 2020 | |
| Primary | The proportion of patients who use radium-223 in combination with other systemic therapies for mCRPC, except luteinising hormone-releasing hormone (LHRH) analogues | Data will be collected from Nov 2013 to Dec 2020 | |
| Primary | The proportion of patients who use radium-223 without having received at least two prior lines of systemic therapy for mCRPC, except LHRH analogues | Data will be collected from Nov 2013 to Dec 2020 | |
| Secondary | The difference between before and after the label change periods in the proportion of patients who use radium-223 in combination with abiraterone acetate | Data will be collected from Nov 2013 to Dec 2020 | |
| Secondary | The difference between before and after the label change periods in the proportion of patients who use radium-223 in combination with other systemic therapies for mCRPC, except luteinising hormone-releasing hormone (LHRH) analogues | Data will be collected from Nov 2013 to Dec 2020 | |
| Secondary | The difference between before and after the label change periods in the proportion of patients who use radium-223 without having received at least two prior lines of systemic therapy for mCRPC, except LHRH analogues | Data will be collected from Nov 2013 to Dec 2020 | |
| Other | Descriptive summary of patient characteristics | Data will be collected from Nov 2013 to Dec 2020 | Including: * Age (in years) * Calendar year when radium-223 was first prescribed/dispensed, as recorded in each data source * Time since first available prostate cancer diagnosis * Confirmed diagnosis (yes/no) of mCRPC * Prior use (yes/no) systemic therapy for CRPC * Prior use (yes/no) systemic therapy for hormone-sensitive prostate cancer (HSPC) * Presence of metastasis at baseline: bone or visceral * Total level of serum alkaline phosphatase, when available: as U/L and categorised as above or below a threshold (e.g., \< 220 U/L and ≥ 220 U/L): * Prior use of bone-health agents (yes/no) since first diagnosis of PC * Prior use of systemic corticosteroids: yes/no, since first diagnosis of PC * History (diagnosis or treated for osteoporosis) of osteoporosis ever before the index date |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04587427
GET https://conductscience.org/api/trials/v1/NCT04587427/registered